Skip to main content
Sign In

Craig T. Jordan, PhD

Dr. Craig Jordan
Craig T. Jordan PhD
University of Colorado School of Medicine
  • Division Chief, Division of Hematology
  • Nancy Carroll Allen Professor of Hematology
  • Professor of Medicine


Contact information
Anschutz Medical Campus

12700 East 19th Ave, Room 9122
Research Complex 2, Campus Box B170
Aurora, CO  80045
Jordan Lab

Dr. Jordan completed his bachelor’s degree at the University of California, Berkeley, followed by doctoral studies at Princeton University with a focus on the molecular biology of hematopoietic stem cells.  He then went on to perform post-doctoral studies at MIT’s Whitehead Institute.  He next spent several years working in the biotechnology industry before rejoining the academic ranks in 1997 at the University of Kentucky as an Assistant Professor of medicine. In 2003 he moved to the University of Rochester, where he became the Director of Translational Research for Hematologic Malignancies at the James P. Wilmot Cancer Center.  In 2013 he was recruited to his present position at the University of Colorado Denver.

Dr. Jordan has been and is an editorial board member or academic editor for several journals including Leukemia, Stem cells, and PLoS Biology and is ad hoc reviewer for numerous journals including Science, Nature, New England Journal of Medicine, Nature Medicine, Cancer Cell, PNAS, Cell Stem Cell, Blood, Cancer Research, Nature Reviews Cancer, Lancet, Nature Reviews Drug Discovery, Drug Discovery Today, etc.  Dr. Jordan has participated in numerous NIH/NCI grant review panels, and has published over 95 peer-reviewed original research articles, review articles and book chapters. He has successfully maintained national level grants including awards from the NIH/NCI, Department of Defense, Leukemia and Lymphoma Society, and American Cancer Society.  His honors include the Helen Hay Whitney Fellowship, the Stohlman Scholar Award from the Leukemia and Lymphoma Society, and the Philip and Marilyn Wehrheim endowed chair in cancer research.
  • University of California, Berkeley, AB, 1984
  • Princeton University, PhD, 1991​
Since first establishing my independent laboratory in 1997, my research has been focused on characterization and targeting of leukemia stem cells (LSCs).  In leukemia, like many forms of cancer, a small subset of so-called “cancer stem cells” are thought to be key drivers of pathogenesis and relapse.  While therapies that reduce bulk tumor have been devised for many forms of cancer, effective eradication of cancer stem cells is more challenging, and represents an important goal towards improved therapies.  In the most prevalent forms of adult acute leukemia, long-term survival rates are only ~20%, hence, better therapies are urgently needed.

My laboratory was the first to describe properties of human LSCs that are relevant to therapeutic targeting.(1,2)  These observations have led to multiple clinical trials using antibodies, small molecules and cell-based immunotherapies designed to target the biological properties first reported from our studies.  Our research was also the first to describe a drug regimen specifically designed to target LSCs in patients.(3)

Building on our initial basic science studies, in subsequent years we developed drug screening and identification methods to identify improved therapeutic agents to target LSCs.  We were the first group to report a single agent (known as parthenolide) capable of selectively eradicating LSCs.(4)  We subsequently collaborated with a leading medicinal chemistry group to develop a candidate clinical compound that was based on parthenolide.(5)  That agent, known as DMAPT is currently being tested in a phase I clinical trial.

In parallel to our efforts to develop novel drugs, we have also generated new methods for drug characterization and new strategies to identify the most basic molecular properties of leukemia stem cells.(6,7) Intriguingly, in recent studies we have identified a distinct subpopulation of LSCs characterized by unique metabolic properties.(8)  This discovery has led to a new therapeutic strategy for targeting LSCs based on pharmacological inhibition of Bcl-2, a concept that we will begin testing in clinical trials in the near future.

  1. Jordan, C. T., Upchurch, D., Szilvassy, S. J., Guzman, M. L., Howard, D. S., Pettigrew, A. L., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D. A., Luger, S. M., and Phillips, G. L. (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777-1784.

  2. Guzman, M. L., Neering, S. J., Upchurch, D., Grimes, B., Howard, D. S., Rizzieri, D. A., Luger, S. M., and Jordan, C. T. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301-2307.

  3. Guzman, M. L., Swiderski, C. F., Howard, D. S., Grimes, B. A., Rossi, R. M., Szilvassy, S. J., and Jordan, C. T. (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Sciences of the United States of America 99, 16220-16225

  4. Guzman, M. L., Rossi, R. M., Karnischky, L., Li, X., Peterson, D. R., Howard, D. S., and Jordan, C. T. (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood

  5. Guzman, M. L., Rossi, R. M., Neelakantan, S., Li, X., Corbett, C. A., Hassane, D. C., Becker, M. W., Bennett, J. M., Sullivan, E., Lachowicz, J. L., Vaughan, A., Sweeney, C. J., Matthews, W., Carroll, M., Liesveld, J. L., Crooks, P. A., and Jordan, C. T. (2007) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110, 4427-4435

  6. Hassane, D. C., Guzman, M. L., Corbett, C., Li, X., Abboud, R., Young, F., Liesveld, J. L., Carroll, M., and Jordan, C. T. (2008) Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood

  7. Ashton, J. M., Balys, M., Neering, S. J., Hassane, D. C., Cowley, G., Root, D. E., Miller, P. G., Ebert, B. L., McMurray, H. R., Land, H., and Jordan, C. T. (2012) Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell 11, 359-372

  8. Lagadinou, E. D., Sach, A., Callahan, K., Rossi, R. M., Neering, S. J., Minhajuddin, M., Ashton, J. M., Pei, S., Grose, V., O'Dwyer, K. M., Liesveld, J. L., Brookes, P. S., Becker, M. W., and Jordan, C. T. (2013) BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329-341
1. Callahan KP, Minhajuddin M, Corbett C, Lagadinou ED, Rossi RM, Grose V, Balys MM, Pan L, Jacob S, Frontier A, Grever MR, Lucas DM, Kinghorn AD, Liesveld JL, Becker MW, Jordan CT.Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.Leukemia. 2014 Feb 28. doi: 10.1038/leu.2014.93. [Epub ahead of print]PubMed [citation] PMID: 24577530
2. Kolev JN, O'Dwyer KM, Jordan CT, Fasan R.Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization.ACS Chem Biol. 2014 Jan 17;9(1):164-73. doi: 10.1021/cb400626w. Epub 2013 Nov 8.PubMed [citation] PMID: 24206617, PMCID: PMC3904131
3. Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL.Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.J Clin Invest. 2014 Jan 2;124(1):222-36. doi: 10.1172/JCI66005. Epub 2013 Dec 16.PubMed [citation] PMID: 24334453, PMCID: PMC3871218
4. Liu S, Miriyala S, Keaton MA, Jordan CT, Wiedl C, Clair DK, Moscow JA.Metabolic effects of acute thiamine depletion are reversed by rapamycin in breast and leukemia cells.PLoS One. 2014;9(1):e85702. doi: 10.1371/journal.pone.0085702.PubMed [citation] PMID: 24454921, PMCID: PMC3893258
5. Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL 2nd.A phase I study of decitabine and rapamycin in relapsed/refractory AML.Leuk Res. 2013 Dec;37(12):1622-7. doi: 10.1016/j.leukres.2013.09.002. Epub 2013 Sep 8.PubMed [citation] PMID: 24138944
6. Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, Benes C, Hagen FK, Munger J, Crooks PA, Becker MW, Jordan CT.Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.J Biol Chem. 2013 Nov 22;288(47):33542-58. doi: 10.1074/jbc.M113.511170. Epub 2013 Oct 2.PubMed [citation] PMID: 24089526, PMCID: PMC3837103
7. Howard DS, Liesveld J, Phillips GL 2nd, Hayslip J, Weiss H, Jordan CT, Guzman ML.A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.Leuk Res. 2013 Nov;37(11):1502-8. doi: 10.1016/j.leukres.2013.09.003. Epub 2013 Sep 8.PubMed [citation] PMID: 24075534
8. Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML.Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.Exp Hematol. 2013 Sep;41(9):799-807.e4. doi: 10.1016/j.exphem.2013.04.012. Epub 2013 May 6.PubMed [citation] PMID: 23660068, PMCID: PMC3809917
9. Sampson ER, McMurray HR, Hassane DC, Newman L, Salzman P, Jordan CT, Land H.Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery.Oncogene. 2013 Aug 15;32(33):3809-18. doi: 10.1038/onc.2012.389. Epub 2012 Sep 10.PubMed [citation] PMID: 22964631, PMCID: PMC3631583
10. Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, Fujisaki J, Silberstein L, Alexe G, Al-Hajj MA, Shelton CA, Armstrong SA, Root DE, et al.In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling.Cancer Cell. 2013 Jul 8;24(1):45-58. doi: 10.1016/j.ccr.2013.05.004. Epub 2013 Jun 13.PubMed [citation] PMID: 23770013, PMCID: PMC3746037
11. Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT.BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.Cell Stem Cell. 2013 Mar 7;12(3):329-41. doi:
10.1016/j.stem.2012.12.013. Epub 2013 Jan 17.PubMed [citation] PMID: 23333149, PMCID: PMC3595363
12. Nielsen TH, Johnson N, Garnier N, Kwan S, Yao L, Cocolakis E, Hébert J, Morgan RA, Paquet E, Callahan KP, Jordan CT, Assouline S, Miller WH Jr, Mann KK.Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient.Front Pharmacol. 2013;4:9. doi: 10.3389/fphar.2013.00009.PubMed [citation] PMID: 23408639, PMCID: PMC3570070
13. Pei S, Jordan CT.How close are we to targeting the leukemia stem cell?Best Pract Res Clin Haematol. 2012 Dec;25(4):415-8. doi: 10.1016/j.beha.2012.10.003. Epub 2012 Oct 23. Review.PubMed [citation] PMID: 23200537
14. Ashton JM, Balys M, Neering SJ, Hassane DC, Cowley G, Root DE, Miller PG, Ebert BL, McMurray HR, Land H, Jordan CT.Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells.Cell Stem Cell. 2012 Sep 7;11(3):359-72. doi: 10.1016/j.stem.2012.05.024. Epub 2012 Aug 2.PubMed [citation] PMID: 22863534
15. Zhao C, Xiu Y, Ashton J, Xing L, Morita Y, Jordan CT, Boyce BF.Noncanonical NF-κB signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions.Stem Cells. 2012 Apr;30(4):709-18. doi: 10.1002/stem.1050.PubMed [citation] PMID: 22290873, PMCID: PMC3602314
16. Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM.Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.Blood. 2012 Jan 12;119(2):540-50. doi: 10.1182/blood-2011-04-348151. Epub 2011 Sep 28.PubMed [citation] PMID: 21957195, PMCID: PMC3384480
17. Becker MW, Jordan CT.Leukemia stemness signatures step toward the clinic.Cell Stem Cell. 2011 Sep 2;9(3):185-6. doi: 10.1016/j.stem.2011.08.006.PubMed [citation] PMID: 21885015
18. Nasim S, Guzman ML, Jordan CT, Crooks PA.Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture.Bioorg Med Chem Lett. 2011 Aug 15;21(16):4879-83. doi: 10.1016/j.bmcl.2011.06.027. Epub 2011 Jun 22.PubMed [citation] PMID: 21757349, PMCID: PMC3725994
19. Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL.Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.Cancer Invest. 2011 Aug;29(7):439-50. doi: 10.3109/07357907.2011.590567.PubMed [citation] PMID: 21740082
20. Becker MW, Jordan CT.Leukemia stem cells in 2010: current understanding and future directions.Blood Rev. 2011 Mar;25(2):75-81. doi: 10.1016/j.blre.2010.11.001. Epub 2011 Jan 8. Review.PubMed [citation] PMID: 21216511
21. Nasim S, Pei S, Hagen FK, Jordan CT, Crooks PA.Melampomagnolide B: a new antileukemic sesquiterpene.Bioorg Med Chem. 2011 Feb 15;19(4):1515-9. doi: 10.1016/j.bmc.2010.12.045. Epub 2011 Jan 6.PubMed [citation] PMID: 21273084
22. Konopleva MY, Jordan CT.Leukemia stem cells and microenvironment: biology and therapeutic targeting.J Clin Oncol. 2011 Feb 10;29(5):591-9. doi: 10.1200/JCO.2010.31.0904. Epub 2011 Jan 10. Review.PubMed [citation] PMID: 21220598
23. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M.Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.PLoS One. 2011;6(8):e23108. doi: 10.1371/journal.pone.0023108. Epub 2011 Aug 11.PubMed [citation] PMID: 21853076, PMCID: PMC3154919
24. Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT.Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways.Blood. 2010 Dec 23;116(26):5983-90. doi: 10.1182/blood-2010-04-278044. Epub 2010 Oct 1.PubMed [citation] PMID: 20889920
25. Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT, Grant S.The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.Br J Haematol. 2010 Oct;151(1):70-83. doi: 10.1111/j.1365-2141.2010.08319.x. Epub 2010 Aug 2.PubMed [citation] PMID: 20701602, PMCID: PMC2950247
26. Silvers CR, Williams K, Salamone L, Huang J, Jordan CT, Zhou H, Palapattu GS.A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors.Prostate. 2010 Sep 15;70(13):1379-87. doi: 10.1002/pros.21171.PubMed [citation] PMID: 20687210, PMCID: PMC3808877
27. Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, Oehler VG, Radich JP, Jordan CT, Reya T.Regulation of myeloid leukaemia by the cell-fate determinant Musashi.Nature. 2010 Aug 5;466(7307):765-8. doi: 10.1038/nature09171. Epub 2010 Jul 18.PubMed [citation] PMID: 20639863, PMCID: PMC2918284
28. Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH.NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus...Biol Blood Marrow Transplant. 2010 Jun;16(6):709-28. doi: 10.1016/j.bbmt.2010.03.002. Epub 2010 Mar 12.PubMed [citation] PMID: 20227509, PMCID: PMC3711411
29. Jordan CT.Targeting myeloid leukemia stem cells.Sci Transl Med. 2010 May 12;2(31):31ps21. doi: 10.1126/scitranslmed.3000914. Review.PubMed [citation] PMID: 20463365
30. Skalska J, Brookes PS, Nadtochiy SM, Hilchey SP, Jordan CT, Guzman ML, Maggirwar SB, Briehl MM, Bernstein SH.Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide.PLoS One. 2009 Dec 2;4(12):e8115. doi: 10.1371/journal.pone.0008115.PubMed [citation] PMID: 19956548, PMCID: PMC2780735
31. Frisch BJ, Porter RL, Gigliotti BJ, Olm-Shipman AJ, Weber JM, O'Keefe RJ, Jordan CT, Calvi LM.In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells.Blood. 2009 Nov 5;114(19):4054-63. doi: 10.1182/blood-2009-03-205823. Epub 2009 Sep 2.PubMed [citation] PMID: 19726721, PMCID: PMC2774547
32. Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, Hsi ED, Abo A.Monoclonal antibodies against IREM-1: potential for targeted therapy of AML.Leukemia. 2009 Sep;23(9):1587-97. doi: 10.1038/leu.2009.99. Epub 2009 May 14.PubMed [citation] PMID: 19440216
33. Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y.Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials.Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1580-91. doi: 10.1016/j.ijrobp.2009.03.047. Epub 2009 Jun 17.PubMed [citation] PMID: 19540073
34. Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA.Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1).Bioorg Med Chem Lett. 2009 Aug 1;19(15):4346-9. doi: 10.1016/j.bmcl.2009.05.092. Epub 2009 May 27.PubMed [citation] PMID: 19505822
35. Rosen JM, Jordan CT.The increasing complexity of the cancer stem cell paradigm.Science. 2009 Jun 26;324(5935):1670-3. doi: 10.1126/science.1171837. Review.PubMed [citation] PMID: 19556499, PMCID: PMC2873047
36. Guzman ML, Jordan CT.Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology.Cancer Cell. 2009 Apr 7;15(4):252-4. doi: 10.1016/j.ccr.2009.03.008.PubMed [citation] PMID: 19345324
37. Jordan CT.Cancer stem cells: controversial or just misunderstood?Cell Stem Cell. 2009 Mar 6;4(3):203-5. doi: 10.1016/j.stem.2009.02.003.PubMed [citation] PMID: 19265659, PMCID: PMC2871155
38. Hewamana S, Lin TT, Jenkins C, Burnett AK, Jordan CT, Fegan C, Brennan P, Rowntree C, Pepper C.The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.Clin Cancer Res. 2008 Dec 15;14(24):8102-11. doi: 10.1158/1078-0432.CCR-08-1673.PubMed [citation] PMID: 19088025
39. Jordan CT.Can we finally target the leukemic stem cells?Best Pract Res Clin Haematol. 2008 Dec;21(4):615-20. doi: 10.1016/j.beha.2008.07.006.PubMed [citation] PMID: 19041600, PMCID: PMC2613248
40. Wang PY, Young F, Chen CY, Stevens BM, Neering SJ, Rossi RM, Bushnell T, Kuzin I, Heinrich D, Bottaro A, Jordan CT.The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.Blood. 2008 Nov 15;112(10):4184-92. doi: 10.1182/blood-2008-02-142190. Epub 2008 Aug 28.PubMed [citation] PMID: 18755985, PMCID: PMC2581986
41. Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW.Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.Ann Oncol. 2008 Oct;19(10):1759-64. doi: 10.1093/annonc/mdn365. Epub 2008 May 25.PubMed [citation] PMID: 18504251, PMCID: PMC2735068
42. Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT.Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.Blood. 2008 Jun 15;111(12):5654-62. doi: 10.1182/blood-2007-11-126003. Epub 2008 Feb 27.PubMed [citation] PMID: 18305216, PMCID: PMC2424160
43. Young FM, Campbell A, Emo KL, Jansson J, Wang PY, Jordan CT, Mullen CA.High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.Biol Blood Marrow Transplant. 2008 Jun;14(6):622-30. doi: 10.1016/j.bbmt.2008.02.015. Epub 2008 Apr 14.PubMed [citation] PMID: 18489987, PMCID: PMC2517424
44. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C.The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.Blood. 2008 May 1;111(9):4681-9. doi: 10.1182/blood-2007-11-125278. Epub 2008 Jan 28.PubMed [citation] PMID: 18227347
45. Mao G, Yuan F, Absher K, Jennings CD, Howard DS, Jordan CT, Gu L.Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression.Cell Res. 2008 Feb;18(2):281-9. doi: 10.1038/cr.2008.14.PubMed [citation] PMID: 18227862
46. Kim SW, Oleksyn DW, Rossi RM, Jordan CT, Sanz I, Chen L, Zhao J.Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.Blood. 2008 Feb 1;111(3):1644-53. Epub 2007 Nov 19.PubMed [citation] PMID: 18025152
47. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT.An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.Blood. 2007 Dec 15;110(13):4427-35. Epub 2007 Sep 5.PubMed [citation] PMID: 17804695, PMCID: PMC2234793
48. Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, Liesveld JL, Hébert J, Young F, Jordan CT.Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8).Blood. 2007 Dec 15;110(13):4436-44. Epub 2007 Sep 4.PubMed [citation] PMID: 17785584, PMCID: PMC2234782
49. Neering SJ, Bushnell T, Sozer S, Ashton J, Rossi RM, Wang PY, Bell DR, Heinrich D, Bottaro A, Jordan CT.Leukemia stem cells in a genetically defined murine model of blast-crisis CML.Blood. 2007 Oct 1;110(7):2578-85. Epub 2007 Jun 29.PubMed [citation] PMID: 17601986, PMCID: PMC1988942
50. Bostrom MA, Boyanovsky BB, Jordan CT, Wadsworth MP, Taatjes DJ, de Beer FC, Webb NR.Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice.Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):600-6. Epub 2007 Jan 4.PubMed [citation] PMID: 17204667
51. Jordan CT.The leukemic stem cell.Best Pract Res Clin Haematol. 2007 Mar;20(1):13-8. Review.PubMed [citation] PMID: 17336250, PMCID: PMC1988840
52. Jordan CT.Searching for leukemia stem cells--not yet the end of the road?Cancer Cell. 2006 Oct;10(4):253-4.PubMed [citation] PMID: 17045202
53. Jordan CT, Guzman ML, Noble M.Cancer stem cells.N Engl J Med. 2006 Sep 21;355(12):1253-61. Review. No abstract available. PubMed [citation] PMID: 16990388
54. Weber JM, Forsythe SR, Christianson CA, Frisch BJ, Gigliotti BJ, Jordan CT, Milner LA, Guzman ML, Calvi LM.Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells.Bone. 2006 Sep;39(3):485-93. Epub 2006 May 2.PubMed [citation] PMID: 16647886
55. Guzman ML, Jordan CT.Feverfew: weeding out the root of leukaemia.Expert Opin Biol Ther. 2005 Sep;5(9):1147-52.PubMed [citation] PMID: 16120045
56. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT.The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.Blood. 2005 Jun 1;105(11):4163-9. Epub 2005 Feb 1.PubMed [citation] PMID: 15687234, PMCID: PMC1895029
57. Jordan CT.Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology.Nat Clin Pract Oncol. 2005 May;2(5):224-5. No abstract available. PubMed [citation] PMID: 16264940
58. Jordan CT.The potential of targeting malignant stem cells as a treatment for leukemia.Future Oncol. 2005 Apr;1(2):205-7. Review.PubMed [citation] PMID: 16555992
59. Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL.Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels.Mol Cell Biol. 2005 Feb;25(3):1100-12.PubMed [citation] PMID: 15657436, PMCID: PMC544005
60. Jordan CT.Cancer stem cell biology: from leukemia to solid tumors.Curr Opin Cell Biol. 2004 Dec;16(6):708-12. Review.PubMed [citation] PMID: 15530785
61. Jordan CT.A new approach to treatment of acute myelogenous leukemia using targeted therapy in combination with standard chemotherapy.Leuk Res. 2004 Nov;28(11):1121-2. No abstract available. PubMed [citation] PMID: 15380333
62. Jordan CT, Guzman ML.Mechanisms controlling pathogenesis and survival of leukemic stem cells.Oncogene. 2004 Sep 20;23(43):7178-87. Review.PubMed [citation] PMID: 15378078
63. Goodrum F, Jordan CT, Terhune SS, High K, Shenk T.Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations.Blood. 2004 Aug 1;104(3):687-95. Epub 2004 Apr 13.PubMed [citation] PMID: 15090458
64. Guzman ML, Jordan CT.Considerations for targeting malignant stem cells in leukemia.Cancer Control. 2004 Mar-Apr;11(2):97-104. Review.PubMed [citation] PMID: 15024346
65. Gilliland DG, Jordan CT, Felix CA.The molecular basis of leukemia.Hematology Am Soc Hematol Educ Program. 2004:80-97. Review.PubMed [citation] PMID: 15561678
66. Liesveld JL, Jordan CT, Phillips GL 2nd.The hematopoietic stem cell in myelodysplasia.Stem Cells. 2004;22(4):590-9. Review.PubMed [citation] PMID: 15277704
67. Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL.Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis.Mol Cell Biol. 2003 Dec;23(24):8992-9002.PubMed [citation] PMID: 14645512, PMCID: PMC309660
68. Goodrum FD, Jordan CT, High K, Shenk T.Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency.Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16255-60. Epub 2002 Nov 27.PubMed [citation] PMID: 12456880, PMCID: PMC138598
69. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, Jordan CT.Preferential induction of apoptosis for primary human leukemic stem cells.Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16220-5. Epub 2002 Nov 25.PubMed [citation] PMID: 12451177, PMCID: PMC138592
70. Gong S, Lu X, Xu Y, Swiderski CF, Jordan CT, Moscow JA.Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias.Exp Hematol. 2002 Oct;30(10):1162-9.PubMed [citation] PMID: 12384147
71. Jordan CT.Unique molecular and cellular features of acute myelogenous leukemia stem cells.Leukemia. 2002 Apr;16(4):559-62. Review.PubMed [citation] PMID: 11960332
72. Srour EF, Jordan CT.Isolation and characterization of primitive hematopoietic cells based on their position in the cell cycle.Methods Mol Med. 2002;63:93-111. doi: 10.1385/1-59259-140-X:093.PubMed [citation] PMID: 21437802
73. Nolta JA, Jordan CT.Spotlight on hematopoietic stem cells: looking beyond dogma. Introduction.Leukemia. 2001 Nov;15(11):1677-80. No abstract available. PubMed [citation] PMID: 11681405
74. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT.Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.Blood. 2001 Oct 15;98(8):2301-7.PubMed [citation] PMID: 11588023
75. Jordan CT, Vanin EF, Marini FC.The use of adenoviral vectors for genetic manipulation and analysis of primitive hematopoietic cells.Curr Gene Ther. 2001 Sep;1(3):257-65. Review.PubMed [citation] PMID: 12109141
76. Guzman ML, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Phillips GL, Jordan CT.Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells.Blood. 2001 Apr 1;97(7):2177-9.PubMed [citation] PMID: 11264190
77. Lemischka IR, Jordan CT.The return of clonal marking sheds new light on human hematopoietic stem cells.Nat Immunol. 2001 Jan;2(1):11-2. No abstract available. PubMed [citation] PMID: 11135569
78. Evans ME, Jordan CT, Chang SM, Conrad C, Gerberding JL, Kaufman HL, Mayhall CG, Nolta JA, Pilaro AM, Sullivan S, Weber DJ, Wivel NA.Clinical infection control in gene therapy: a multidisciplinary conference.Infect Control Hosp Epidemiol. 2000 Oct;21(10):659-73. Review.PubMed [citation] PMID: 11083185
79. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL.The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.Leukemia. 2000 Oct;14(10):1777-84.PubMed [citation] PMID: 11021753
80. Howard DS, Rizzierri DA, Grimes B, Upchurch D, Phillips GL, Stewart AK, Yannelli JR, Jordan CT.Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer.Leukemia. 1999 Oct;13(10):1608-16.PubMed [citation] PMID: 10516763
81. Rosenzweig M, MacVittie TJ, Harper D, Hempel D, Glickman RL, Johnson RP, Farese AM, Whiting-Theobald N, Linton GF, Yamasaki G, Jordan CT, Malech HL.Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning.Blood. 1999 Oct 1;94(7):2271-86.PubMed [citation] PMID: 10498599
82. Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM.Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors.Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2988-93.PubMed [citation] PMID: 10077624, PMCID: PMC15882
83. Jordan CT, Van Zant G.Recent progress in identifying genes regulating hematopoietic stem cell function and fate.Curr Opin Cell Biol. 1998 Dec;10(6):716-20. Review.PubMed [citation] PMID: 9914177
84. Bregni M, Shammah S, Malaffo F, Di Nicola M, Milanesi M, Magni M, Matteucci P, Ravagnani F, Jordan CT, Siena S, Gianni AM.Adenovirus vectors for gene transduction into mobilized blood CD34+ cells.Gene Ther. 1998 Apr;5(4):465-72.PubMed [citation] PMID: 9614570
85. Harrison DE, Zhong RK, Jordan CT, Lemischka IR, Astle CM.Relative to adult marrow, fetal liver repopulates nearly five times more effectively long-term than short-term.Exp Hematol. 1997 Apr;25(4):293-7.PubMed [citation] PMID: 9131003
86. Orlic D, Girard LJ, Anderson SM, Do BK, Seidel NE, Jordan CT, Bodine DM.Transduction efficiency of cell lines and hematopoietic stem cells correlates with retrovirus receptor mRNA levels.Stem Cells. 1997;15 Suppl 1:23-8; discussion 28-9.PubMed [citation] PMID: 9368321
87. Orlic D, Girard LJ, Jordan CT, Anderson SM, Cline AP, Bodine DM.The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction.Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11097-102.PubMed [citation] PMID: 8855315, PMCID: PMC38290
88. Jordan CT, Yamasaki G, Minamoto D.High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations.Exp Hematol. 1996 Sep;24(11):1347-55.PubMed [citation] PMID: 8862447
89. Neering SJ, Hardy SF, Minamoto D, Spratt SK, Jordan CT.Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors.Blood. 1996 Aug 15;88(4):1147-55.PubMed [citation] PMID: 8695831
90. Jordan CT, Astle CM, Zawadzki J, Mackarehtschian K, Lemischka IR, Harrison DE.Long-term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation.Exp Hematol. 1995 Aug;23(9):1011-5.PubMed [citation] PMID: 7635180
91. Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, Hooley J, Bauer K, Matthews W.Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells.Blood. 1994 Oct 15;84(8):2422-30.PubMed [citation] PMID: 7919361
92. Harrison DE, Jordan CT, Zhong RK, Astle CM.Primitive hemopoietic stem cells: direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations.Exp Hematol. 1993 Feb;21(2):206-19. Review.PubMed [citation] PMID: 8425559
93. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR.A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit.Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9026-30.PubMed [citation] PMID: 1717995, PMCID: PMC52644
94. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR.A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations.Cell. 1991 Jun 28;65(7):1143-52.PubMed [citation] PMID: 1648448
95. Jordan CT, McKearn JP, Lemischka IR.Cellular and developmental properties of fetal hematopoietic stem cells.Cell. 1990 Jun 15;61(6):953-63.PubMed [citation] PMID: 1972037
96. Jordan CT, Lemischka IR.Clonal and systemic analysis of long-term hematopoiesis in the mouse.Genes Dev. 1990 Feb;4(2):220-32.PubMed [citation] PMID: 1970972
97. Oncogene cooperativity analysis reveals a novel set of genes that regulate the in vivo growth and survival of leukemia stem cells Oncogene cooperativity analysis reveals a novel set of genes that regulate the in vivo growth and survival of leukemia stem cells. Cell stem cell. My Bibliography [journal]